Disease relevance of Aethylbutylbarbitursaeure

• Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight [1].
• Furthermore, neonal -lasma, which had lower fibrinogen and factor-VIII content than maternal plasma, facilitated maternal platelet aggregation by ristocetin and showed a greater ability than maternal plasma to promote ristocetin-induced aggregation of platelets of a patient with von Willebrand's disease [2].
• 4 We conclude that redistribution of butobarbitone into adipose tissues can explain the obtained results and that obesity modifies the pharmacokinetics of the drug [1].
• Charcoal haemoperfusion was successful in the treatment of severe butobarbitone poisoning complicated by resistant hypotension [3].
• We evaluated the efficacy of non-competitive N-methyl-D-aspartate receptor antagonist MK-801 (dizocilpine) as an adjuvant therapy in experimental neonal bacterial meningitis [4].

High impact information on Aethylbutylbarbitursaeure

• Four barbiturates, barbituric acid, butethal, phenobarbital, and 2-thiobarbituric acid, of fourteen tested were found to induce accumulation of benzophenanthridine alkaloids in cell suspension cultures of the California poppy Eschscholzia california [5].
• During steady-state infusion with various barbiturate concentrations (barbital, 1 g/L; butethal, 0.1, 1 g/L), a bolus containing [3H]water (cellular space marker) and [14C]barbital was injected into the portal vein [6].

Analytical, diagnostic and therapeutic context of Aethylbutylbarbitursaeure

• After oral administration of 200 mg butobarbitone, concentration of the intact drug was measured by gas liquid chromatographic assay in urine samples collected during 72 h and at three times in blood [1].
• The effect of anti-amoebic drug therapy on the metabolism of butobarbitone [7].

References